Publication | Closed Access

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

Second-line TreatmentThrombosisThrombopoiesisRitp TrialAutoimmune DiseaseSystemic TreatmentHematologyImmunologyAdult Immune ThrombocytopeniaPharmacotherapyImmunotherapyMedicine